Tirzepatide

Dual GIP and GLP-1 Receptor Agonist

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Available as FDA-approved Mounjaro® for Type 2 diabetes and Zepbound® for weight management and obstructive sleep apnea. It provides superior weight loss and glycemic control compared to single-pathway medications through its unique dual mechanism of action.

Technical Specifications

Molecular Information

Molecular Weight4,813 Da

FormulaC225H348N48O68

CAS Number1247405-47-9

Amino Acid Sequence

39-amino acid synthetic peptide

Storage & Handling

Refrigerated storage required. Pre-filled pens or vials. Store at 36-46°F (2-8°C).

STORAGE REQUIREMENTS

Temperature2-8°C (36-46°F)

Light exposureStore in original carton

HumidityDo not freeze

Shelf life21 days after first use

Medical Disclaimer

Tirzepatide is FDA-approved as Mounjaro® for Type 2 diabetes and Zepbound® for chronic weight management. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all therapeutic uses.